Free Trial

Corbus Pharmaceuticals (CRBP) Competitors

Corbus Pharmaceuticals logo
$16.32 +0.78 (+5.02%)
Closing price 04:00 PM Eastern
Extended Trading
$16.26 -0.05 (-0.34%)
As of 07:22 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

CRBP vs. TBPH, TERN, NRIX, GYRE, ARVN, ERAS, GHRS, MGTX, SNDL, and ESPR

Should you be buying Corbus Pharmaceuticals stock or one of its competitors? The main competitors of Corbus Pharmaceuticals include Theravance Biopharma (TBPH), Terns Pharmaceuticals (TERN), Nurix Therapeutics (NRIX), Gyre Therapeutics (GYRE), Arvinas (ARVN), Erasca (ERAS), GH Research (GHRS), MeiraGTx (MGTX), SNDL (SNDL), and Esperion Therapeutics (ESPR). These companies are all part of the "pharmaceutical products" industry.

Corbus Pharmaceuticals vs. Its Competitors

Corbus Pharmaceuticals (NASDAQ:CRBP) and Theravance Biopharma (NASDAQ:TBPH) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, risk, analyst recommendations, profitability, earnings, media sentiment, institutional ownership and valuation.

Corbus Pharmaceuticals has higher earnings, but lower revenue than Theravance Biopharma. Corbus Pharmaceuticals is trading at a lower price-to-earnings ratio than Theravance Biopharma, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Corbus PharmaceuticalsN/AN/A-$40.21M-$4.76-3.43
Theravance Biopharma$64.38M10.89-$56.42M$0.2458.00

Corbus Pharmaceuticals has a beta of 2.84, indicating that its share price is 184% more volatile than the S&P 500. Comparatively, Theravance Biopharma has a beta of -0.03, indicating that its share price is 103% less volatile than the S&P 500.

Corbus Pharmaceuticals currently has a consensus price target of $45.43, indicating a potential upside of 178.36%. Theravance Biopharma has a consensus price target of $23.00, indicating a potential upside of 65.23%. Given Corbus Pharmaceuticals' higher possible upside, equities analysts clearly believe Corbus Pharmaceuticals is more favorable than Theravance Biopharma.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Corbus Pharmaceuticals
1 Sell rating(s)
0 Hold rating(s)
8 Buy rating(s)
1 Strong Buy rating(s)
2.90
Theravance Biopharma
0 Sell rating(s)
2 Hold rating(s)
2 Buy rating(s)
2 Strong Buy rating(s)
3.00

64.6% of Corbus Pharmaceuticals shares are owned by institutional investors. Comparatively, 99.1% of Theravance Biopharma shares are owned by institutional investors. 4.0% of Corbus Pharmaceuticals shares are owned by company insiders. Comparatively, 6.9% of Theravance Biopharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

In the previous week, Theravance Biopharma had 1 more articles in the media than Corbus Pharmaceuticals. MarketBeat recorded 5 mentions for Theravance Biopharma and 4 mentions for Corbus Pharmaceuticals. Theravance Biopharma's average media sentiment score of 0.69 beat Corbus Pharmaceuticals' score of 0.62 indicating that Theravance Biopharma is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Corbus Pharmaceuticals
0 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Theravance Biopharma
1 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Theravance Biopharma has a net margin of 16.88% compared to Corbus Pharmaceuticals' net margin of 0.00%. Theravance Biopharma's return on equity of 6.93% beat Corbus Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Corbus PharmaceuticalsN/A -43.65% -39.62%
Theravance Biopharma 16.88%6.93%3.52%

Summary

Theravance Biopharma beats Corbus Pharmaceuticals on 11 of the 15 factors compared between the two stocks.

Get Corbus Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for CRBP and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CRBP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CRBP vs. The Competition

MetricCorbus PharmaceuticalsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$190.45M$2.61B$6.04B$10.46B
Dividend YieldN/A57.77%5.73%4.79%
P/E RatioN/A22.5785.3127.07
Price / SalesN/A643.65591.31190.92
Price / CashN/A25.7125.7330.17
Price / Book1.405.3212.666.69
Net Income-$40.21M$32.98M$3.31B$276.03M
7 Day Performance12.40%0.94%-0.44%-1.13%
1 Month Performance71.79%9.70%8.70%6.49%
1 Year Performance-13.10%-0.42%76.70%34.41%

Corbus Pharmaceuticals Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CRBP
Corbus Pharmaceuticals
3.9377 of 5 stars
$16.32
+5.0%
$45.43
+178.4%
-17.3%$190.45MN/A0.0040
TBPH
Theravance Biopharma
3.2089 of 5 stars
$14.58
+1.2%
$23.00
+57.8%
+68.4%$725.70M$77.21M60.75110
TERN
Terns Pharmaceuticals
3.6945 of 5 stars
$8.43
+2.4%
$15.49
+83.7%
+6.3%$720.22MN/A-8.1140
NRIX
Nurix Therapeutics
1.7289 of 5 stars
$9.95
+6.1%
$29.07
+192.2%
-58.7%$717.09M$54.55M-3.81300Earnings Report
Analyst Forecast
GYRE
Gyre Therapeutics
1.5551 of 5 stars
$7.34
-0.9%
$18.00
+145.2%
-39.7%$713.68M$105.76M734.7340Analyst Forecast
ARVN
Arvinas
2.9587 of 5 stars
$9.62
+0.1%
$16.18
+68.2%
-63.8%$705.54M$263.40M-9.52420
ERAS
Erasca
2.5287 of 5 stars
$2.33
-3.7%
$3.71
+59.4%
-12.2%$686.48MN/A-5.18120
GHRS
GH Research
2.7186 of 5 stars
$13.06
-0.3%
$32.00
+145.0%
+83.3%$681.57MN/A-17.6510News Coverage
Analyst Forecast
MGTX
MeiraGTx
4.1031 of 5 stars
$8.41
-0.5%
$24.00
+185.4%
+84.5%$679.78M$33.28M-4.12300
SNDL
SNDL
3.2813 of 5 stars
$2.56
-0.8%
$4.50
+75.8%
+26.6%$677.96M$671.81M-9.482,516
ESPR
Esperion Therapeutics
3.7052 of 5 stars
$3.12
-5.5%
$7.00
+124.4%
+28.4%$665.35M$332.31M-6.37200

Related Companies and Tools


This page (NASDAQ:CRBP) was last updated on 10/13/2025 by MarketBeat.com Staff
From Our Partners